# What's new in Parkinson's disease research

## Randomized Controlled Trials

**Acupuncture versus sham acupuncture in the treatment of insomnia for patients with Parkinson's disease: a randomized controlled clinical trial.**  
A randomized controlled trial found that acupuncture significantly improved sleep quality in patients with Parkinson's disease-related insomnia compared to sham acupuncture, supporting its safety and efficacy for this indication.  
*Citation: Acupuncture versus sham acupuncture in the treatment of insomnia for patients with Parkinson's disease: a randomized controlled clinical trial, BMC complementary medicine and therapies, 07/19/2025, PMID: 40684211 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40684211))*

## Observational Studies (cohort studies, case-control studies, cross-sectional studies)

**Detecting delirium in Parkinson's disease: an evaluation of diagnostic accuracy of bedside tools.**  
This study in hospitalized PD patients found that bedside tools, particularly the 4AT, have good sensitivity for delirium detection, but caution is warranted in those with cognitive impairment due to reduced accuracy.  
*Citation: Detecting delirium in Parkinson's disease: an evaluation of diagnostic accuracy of bedside tools., Age and ageing, 07/01/2025, PMID: 40684269 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40684269))*

**Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome.**  
Poorer baseline language function predicted more rapid clinical progression and greater gray matter atrophy in PSP-Richardson syndrome, suggesting the value of language assessments as prognostic markers.  
*Citation: Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome., Alzheimer's & dementia, 07/01/2025, PMID: 40684253 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40684253))*

**The correlation between RLS and motor or other non-motor symptoms of PD patients: an observational study.**  
No abstract available for summarization.  
*Citation: The correlation between RLS and motor or other non-motor symptoms of PD patients: an observational study., BMC neurology, 07/19/2025, PMID: 40684087 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40684087))*

**Unlocking the daily impact of parkinson's challenges through a comprehensive assessment using the ChulaPD ADL questionnaire.**  
The ChulaPD ADL questionnaire was validated as a reliable tool for assessing daily living limitations in PD patients and correlates well with disease severity and progression markers.  
*Citation: Unlocking the daily impact of parkinson's challenges through a comprehensive assessment using the ChulaPD ADL questionnaire., Scientific reports, 07/19/2025, PMID: 40683930 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683930))*

**Longitudinal association between plasma epidermal growth factor and the progression of anxiety and depressive symptoms in Parkinson's disease.**  
Higher baseline plasma epidermal growth factor was associated with slower progression of anxiety and depressive symptoms in early PD, indicating its potential as a biomarker and therapeutic target for neuropsychiatric symptoms.  
*Citation: Longitudinal association between plasma epidermal growth factor and the progression of anxiety and depressive symptoms in Parkinson's disease., Psychoneuroendocrinology, 07/14/2025, PMID: 40683110 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683110))*

**Neuropsychiatric fluctuations in Parkinson's disease: A French multicenter study of the NFS psychometric properties.**  
This multicenter study confirmed that the Neuropsychiatric Fluctuation Scale is a reliable and sensitive tool for assessing neuropsychiatric fluctuations in PD patients.  
*Citation: Neuropsychiatric fluctuations in Parkinson's disease: A French multicenter study of the NFS psychometric properties., Parkinsonism & related disorders, 07/11/2025, PMID: 40683099 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683099))*

**The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia.**  
Blood-based biomarkers such as NfL, GFAP, and p-tau181 improve differentiation between PD, AD, FTD, and atypical parkinsonisms, supporting their clinical utility in identifying neurodegenerative diseases.  
*Citation: The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia., Journal of the neurological sciences, 07/11/2025, PMID: 40682931 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40682931))*

**Identifying individuals at-risk of developing Parkinson's disease using a population-based recruitment strategy: The Healthy Brain Ageing Kassel Study.**  
A large-scale, stepwise screening approach in Germany effectively identified individuals at high risk for PD for inclusion in prodromal cohorts and future preventive trials.  
*Citation: Identifying individuals at-risk of developing Parkinson's disease using a population-based recruitment strategy: The Healthy Brain Ageing Kassel Study., NPJ Parkinson's disease, 07/18/2025, PMID: 40681552 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40681552))*

**Peripheral Blood Mononuclear Cell Mitochondrial Bioenergetics Is Impaired in De Novo Parkinson's Disease.**  
Newly diagnosed, untreated PD patients exhibit altered PBMC mitochondrial bioenergetics, with reduced spare capacity correlating with motor severity, supporting mitochondrial function as an early biomarker.  
*Citation: Peripheral Blood Mononuclear Cell Mitochondrial Bioenergetics Is Impaired in De Novo Parkinson's Disease., Molecular neurobiology, 07/18/2025, PMID: 40681825 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40681825))*

**Utilization of home-based traditional Chinese medicine in a homebound population under the integrated home-based medical care program in Taiwan.**  
Home-based traditional Chinese medicine is rarely used among homebound older adults in Taiwan, though it is more frequently utilized for neurodegenerative diseases including PD, with access showing significant social and geographical disparities.  
*Citation: Utilization of home-based traditional Chinese medicine in a homebound population under the integrated home-based medical care program in Taiwan., Journal of the Formosan Medical Association, 07/17/2025, PMID: 40681430 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40681430))*

## Basic Science Research

**Activated TBK1 promotes ACSL1-mediated microglia lipid droplet accumulation and neuroinflammation in Parkinson's disease.**  
No abstract available for summarization.  
*Citation: Activated TBK1 promotes ACSL1-mediated microglia lipid droplet accumulation and neuroinflammation in Parkinson's disease., Journal of neuroinflammation, 07/19/2025, PMID: 40684214 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40684214))*

**Sex differences distinguish performance in four object recognition-based memory tasks in the Pink1-/- rat model of Parkinson's disease.**  
Pink1-/- rats demonstrated sex-dependent cognitive deficits, with male rats exhibiting earlier and more pronounced impairments, mirroring the greater early cognitive vulnerability in men with PD.  
*Citation: Sex differences distinguish performance in four object recognition-based memory tasks in the Pink1-/- rat model of Parkinson's disease., Physiology & behavior, 07/17/2025, PMID: 40683615 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683615))*

**Pharmacodynamics, safety pharmacology and local tolerance of rotigotine behenate extended-release microspheres.**  
Extended-release rotigotine microspheres provided sustained dopaminergic stimulation with promising safety and pharmacological profiles in preclinical models, supporting further clinical development in PD.  
*Citation: Pharmacodynamics, safety pharmacology and local tolerance of rotigotine behenate extended-release microspheres., Toxicology and applied pharmacology, 07/17/2025, PMID: 40683571 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683571))*

**Secretory autophagy mediates lysosomal and autophagic degradation for α-synuclein proteostasis.**  
Disruption of secretory autophagy impairs degradation of aggregate-prone α-synuclein and lysosomal function, highlighting the collaborative role of autophagic pathways in maintaining neuronal proteostasis.  
*Citation: Secretory autophagy mediates lysosomal and autophagic degradation for α-synuclein proteostasis., The Journal of biological chemistry, 07/17/2025, PMID: 40683447 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683447))*

**The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease.**  
The dual GLP-1/GIP agonist DA3-CH provided greater neuroprotection than liraglutide in PD model mice, acting via activation of the Wnt/β-catenin pathway and reduction of PD-associated protein markers.  
*Citation: The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease., European journal of pharmacology, 07/17/2025, PMID: 40683437 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683437))*

**Synaptic enrichment of pSer129 alpha-synuclein correlates with dopaminergic denervation in early-stage Parkinson's disease.**  
Synaptic accumulation of phosphorylated α-synuclein in putaminal dopaminergic terminals is an early event in PD and correlates with terminal loss, supporting its role in early pathogenesis.  
*Citation: Synaptic enrichment of pSer129 alpha-synuclein correlates with dopaminergic denervation in early-stage Parkinson's disease., Nature communications, 07/18/2025, PMID: 40681493 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40681493))*

**YOD1 regulates oxidative damage of dopamine neurons in Parkinson's disease by deubiquitinating PKM2.**  
YOD1 is an oxidative-stress-sensitive regulator in PD that promotes neuronal injury via deubiquitination of PKM2; targeting YOD1 may represent a new therapeutic avenue.  
*Citation: YOD1 regulates oxidative damage of dopamine neurons in Parkinson's disease by deubiquitinating PKM2., Clinical and translational medicine, 07/01/2025, PMID: 40681475 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40681475))*

**mTOR-Mediated Protection Against Atrazine-Induced Ferroptosis and Dopaminergic Neurodegeneration in Parkinson's Disease Models.**  
Overactivation of mTOR confers protection against atrazine-induced ferroptosis and dopaminergic neuron loss in PD models by modulating the GPX4 pathway, suggesting therapeutic potential for targeting mTOR signaling.  
*Citation: mTOR-Mediated Protection Against Atrazine-Induced Ferroptosis and Dopaminergic Neurodegeneration in Parkinson's Disease Models., Molecular neurobiology, 07/19/2025, PMID: 40681827 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40681827))*

## Meta-analyses and Systematic Reviews

_No recent meta-analyses or systematic reviews identified in this update._

## Narrative Reviews

**Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies.**  
This review discusses how evolving biomarker frameworks are transforming the diagnosis, research, and potential unification of dementia with Lewy bodies and Parkinson's disease under shared pathobiologies, with implications for clinical care and trials.  
*Citation: Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies., Alzheimer's & dementia, 07/01/2025, PMID: 40684248 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40684248))*

**Focused ultrasound therapy for movement disorders.**  
The review explores MR-guided focused ultrasound as a minimally invasive treatment for movement disorders such as Parkinson's disease, summarizing its expanding clinical indications and potential future applications.  
*Citation: Focused ultrasound therapy for movement disorders., The Lancet. Neurology, 08/01/2025, PMID: 40683278 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683278))*

**α-synuclein biomarker assays: bridging research and patient care.**  
This article reviews the promise and current limitations of α-synuclein biomarker assays for early and differential diagnosis of Parkinson's disease and other synucleinopathies.  
*Citation: α-synuclein biomarker assays: bridging research and patient care., The Lancet. Neurology, 08/01/2025, PMID: 40683277 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683277))*

**Accelerating the path towards a cure for Parkinson's disease.**  
No abstract available for summarization.  
*Citation: Accelerating the path towards a cure for Parkinson's disease., The Lancet. Neurology, 08/01/2025, PMID: 40683258 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683258))*

**An appraisal at a glance of metallome and disease biomarkers.**  
This review covers the roles of metals and metal-related biomarkers in neurological and autoimmune diseases, including Parkinson's, and advocates for integrated 'multiomics' approaches to increase insight into these complex conditions.  
*Citation: An appraisal at a glance of metallome and disease biomarkers., European journal of medicinal chemistry, 07/03/2025, PMID: 40683147 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683147))*

**Decoding the Dialogue: Immunity and central nervous system interactions in neurodegenerative diseases.**  
The review details how neuroimmune interactions, including innate and adaptive responses, contribute to pathogenesis across neurodegenerative diseases, with a focus on mediators like microglia, astrocytes, and the blood-brain barrier.  
*Citation: Decoding the Dialogue: Immunity and central nervous system interactions in neurodegenerative diseases., The Egyptian journal of immunology, 07/01/2025, PMID: 40682794 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40682794))*

**Opportunities and challenges for deep brain stimulation electrode-guided neurofeedback for symptom mitigation in neurological and psychiatric disorders.**  
This review outlines the potential of using deep brain stimulation electrodes for neurofeedback in PD and other disorders, highlighting technological challenges and the need for larger clinical studies.  
*Citation: Opportunities and challenges for deep brain stimulation electrode-guided neurofeedback for symptom mitigation in neurological and psychiatric disorders., Journal of neuroengineering and rehabilitation, 07/18/2025, PMID: 40682108 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40682108))*

**Metabolic Dysregulation in Parkinson's Disease: Non-Oxidative Phosphorylation and Its Role in Brain Energy Metabolism.**  
The review explores non-oxidative phosphorylation pathways as compensatory mechanisms in PD, suggesting personalized treatment approaches targeting metabolic and mitochondrial dysfunction.  
*Citation: Metabolic Dysregulation in Parkinson's Disease: Non-Oxidative Phosphorylation and Its Role in Brain Energy Metabolism., Aging and disease, 07/06/2025, PMID: 40681352 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40681352))*

**Unveiling the Molecular Pathogenesis of MCPH: Insights From Drosophila Model System.**  
Focusing on primary microcephaly, this review also describes how Drosophila models help understand genetic pathways relevant to human neurodevelopmental and neurodegenerative disorders, including Parkinson's disease.  
*Citation: Unveiling the Molecular Pathogenesis of MCPH: Insights From Drosophila Model System., Development, growth & differentiation, 07/19/2025, PMID: 40682423 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40682423))*

## Case Reports & Case Series

_No recent case reports or case series identified in this update._

## Other

**Decision tree for severity assessment of neurodegenerative diseases using possibility approach and gait dynamics.**  
A decision tree-based, gait analysis model accurately classified type and severity of neurodegenerative diseases, offering a reliable, objective method for clinical assessment in conditions such as PD, ALS, and Huntington's disease.  
*Citation: Decision tree for severity assessment of neurodegenerative diseases using possibility approach and gait dynamics., Scientific reports, 07/19/2025, PMID: 40683959 ([URL](https://www.ncbi.nlm.nih.gov/pubmed/40683959))*

---

*End of document.*